StreetInsider.com News Articles

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

REYKJAVÍK, Iceland, Aug. 18, 2026 /PRNewswire/ -- Össur, a global leader in prosthetics innovation, today announced the renewal of its exclusive partnership with Paralympic gold medalist Hunter Woodhall, extending a relationship that has spanned more than a decade, through the Los Angeles 2028 Paralympic Games.

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

ÖSSUR RENEWS PARTNERSHIP WITH HUNTER WOODHALL THROUGH 2028

Tue, 18 Aug 2026 10:23:00 -0400

Paralympic Gold Medalist and Team Össur Athlete to Continue Prosthetics
Collaboration Through the Los Angeles 2028 Paralympic Games

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025

Sveinn Sölvason, President and CEO, comments:

"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.

Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish

Embla Medical hf: Interim Report Q4 and Full Year 2025

Tue, 03 Feb 2026 01:17:00 -0400

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026

Interim Report Q4 and Full Year 2025
Sveinn Sölvason, President and CEO, comments:
"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.
Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish